244 related articles for article (PubMed ID: 12774774)
41. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
42. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
43. Phenotype and genotype characterization and twin association in patients with Anderson-Fabry cardiomyopathy.
Gomez M; Molina L; Cladellas M; Ascoeta S; Soler C; Ble M; Ramirez A; Bruguera J
Cardiology; 2012; 121(2):71-5. PubMed ID: 22378313
[TBL] [Abstract][Full Text] [Related]
44. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
45. [Clinical courses of two male siblings on hemodialysis for Fabry disease ].
Itoh K; Tanaka M; Matsushita K; Miyamura N; Nishida K; Araki E; Nonoguchi H; Tomita K
Nihon Jinzo Gakkai Shi; 2005; 47(2):121-7. PubMed ID: 15859134
[TBL] [Abstract][Full Text] [Related]
46. [Cornea verticillata - a clinical marker of Fabry disease: case report].
Cordeiro CA; Oréfice F; Lasmar EP; Santos HH; Valadares ER
Arq Bras Oftalmol; 2007; 70(4):701-5. PubMed ID: 17906770
[TBL] [Abstract][Full Text] [Related]
47. Anderson-Fabry disease: developments in diagnosis and treatment.
Kes VB; Cesarik M; Zavoreo I; Madzar Z; Demarin V
Acta Clin Croat; 2012 Sep; 51(3):411-7. PubMed ID: 23330407
[TBL] [Abstract][Full Text] [Related]
48. Renal variant of Anderson-Fabry disease and bilateral renal cell carcinoma.
Blanco J; Herrero J; Arias LF; Garcia-Miralles N; Gamez C; Barrientos A
Pathol Res Pract; 2005; 200(11-12):857-60. PubMed ID: 15792133
[TBL] [Abstract][Full Text] [Related]
49. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
50. Anderson-Fabry disease with cerebrovascular complications in two Italian families.
Borsini W; Giuliacci G; Torricelli F; Pelo E; Martinelli F; Scordo MR
Neurol Sci; 2002 Jun; 23(2):49-53. PubMed ID: 12235491
[TBL] [Abstract][Full Text] [Related]
51. Sickle cell disease and the kidney.
Scheinman JI
Semin Nephrol; 2003 Jan; 23(1):66-76. PubMed ID: 12563602
[TBL] [Abstract][Full Text] [Related]
52. Unexpected Fabry disease in a renal allograft kidney: an underrecognized cause of poor allograft function.
Kochar O; Wick MR; Kerr SE; Oglesbee D; Cathro HP
Ultrastruct Pathol; 2011 Apr; 35(2):92-6. PubMed ID: 21299350
[TBL] [Abstract][Full Text] [Related]
53. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
54. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Gupta S; Ries M; Kotsopoulos S; Schiffmann R
Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
[TBL] [Abstract][Full Text] [Related]
55. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients.
Morgan SH; Rudge P; Smith SJ; Bronstein AM; Kendall BE; Holly E; Young EP; Crawfurd MD; Bannister R
Q J Med; 1990 May; 75(277):491-507. PubMed ID: 2167495
[TBL] [Abstract][Full Text] [Related]
56. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).
Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G;
Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285
[TBL] [Abstract][Full Text] [Related]
57. [Renal lesions in patients with Fabry's disease].
Gubler MC
Rev Med Interne; 2010 Dec; 31 Suppl 2():S220-5. PubMed ID: 21211668
[TBL] [Abstract][Full Text] [Related]
58. Neurological manifestation of Fabry disease--a case report.
Demarin V; Kes VB; Bitunjac M; Ivanković M
Coll Antropol; 2009 Dec; 33 Suppl 2():177-9. PubMed ID: 20120409
[TBL] [Abstract][Full Text] [Related]
59. [Ophthalmic manifestations in Mexican patients with Fabry disease].
Beltrán-Becerra KJ; Ríos-González BE; Gutiérrez-Amavizca BE; Silva-Noriega DA; Figuera LE
Arch Soc Esp Oftalmol; 2012 Nov; 87(11):373-5. PubMed ID: 23058197
[TBL] [Abstract][Full Text] [Related]
60. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
